A Phase 3 interventional study of intravitreous aflibercept and Bevacizumab + Deferred Aflibercept Group in Diabetic Macular Edema, sponsored by Jaeb Center for Health Research. Completed at 54 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Jaeb Center for Health Research · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing bevacizumab in Macular Edema — 3 open to participants now, 3 under way, 2 of them phase 3. Bevacizumab · Macular Edema.
Among the 50 studies testing bevacizumab in Macular Edema, this one is the 7th largest by enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2017, is one of 17 in phase 3, and was the 44th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →3 of the 50 studies testing bevacizumab in Macular Edema are open now, in 2 countries. Recruiting first, the newest first:
Isfahan University of Medical Sciences · Sites in Iran, Islamic Republic of
Ages 40+
Khyber Teaching Hospital · Sites in Pakistan
Birmingham and Midland Eye Centre Sandwell and west Birmingham NHS trust
Ages 18+
By country, each count listing its studies:
Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 16 · Phase 3 24 · Phase 4 13
First in 2005; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 270 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 63 across the 46 interventional studies. Of the 33 that completed or were terminated, 13 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 50 have an industry lead sponsor. The 10 most frequent:
Jaeb Center for Health Research is the lead sponsor of 129 studies on the registry; 16 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
Jaeb Center for Health Research has 9 studies filed under Macular Edema — fewer than ten, so there is no comparison to draw.
1 of the studies testing bevacizumab in Macular Edema that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07897630Phase 3Khyber Teaching HospitalSuprachoroidal Bevacizumab Versus Intravitreal Bevacizumab in Diabetic Macular Edema | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 50 studies testing bevacizumab in Macular Edema, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Both aflibercept and bevacizumab have been shown to improve vision in eyes with DME. In eyes with DME and at least moderate vision loss, both aflibercept and bevacizumab were also shown to be successful in many eyes. However, aflibercept was shown to be more effective at improving vision, on average, at 1 year and at 2 years. Due to the large cost difference between the two drugs, many clinicians and patients are choosing to initiate treatment with bevacizumab and then switch to aflibercept depending on the eye's response to bevacizumab treatment. However, there is no scientific evidence that this treatment strategy is as effective at improving vision as initiating treatment with aflibercept. Patients and clinicians do not know if this approach ultimately has deleterious effects on visual acuity. If starting with aflibercept is not better than starting with bevacizumab and switching to aflibercept if needed, the potential cost savings to future patients and the health care system would be substantial. However, if starting with aflibercept is better, then patients, clinicians, and health care providers can make informed decisions for how to best treat patients with DME and at least moderate vision loss.
Study Objectives To compare the efficacy of intravitreous aflibercept with intravitreous bevacizumab + deferred aflibercept if needed in eyes with CI DME and moderate vision loss
Participant-level Criteria Inclusion
To be eligible, the following inclusion criteria must be met:
Diagnosis of diabetes mellitus (type 1 or type 2)
Current regular use of insulin for the treatment of diabetes Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes Documented diabetes by American Diabetes Association and/or World Health Organization criteria
Able and willing to provide .
Exclusion
An individual is not eligible if any of the following exclusion criteria are present:
A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control).
Participation in an trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval for the indication being studied at the time of study entry.
Blood pressure > 180/110 (systolic above 180 OR diastolic above 110).
Systemic anti-VEGF or pro-VEGF treatment within four months prior to randomization or anticipated use during the study.
For women of : pregnant or lactating or intending to become pregnant within the next 24 months.
Study Eye Criteria The study participant must have at least one eye meeting all of the inclusion criteria and none of the exclusion criteria listed below.
Study participants can have two study eyes only if both eyes are eligible at the time of randomization. For study participants with two eligible eyes, the logistical complexities of the protocol must be considered for each individual prior to randomizing both eyes.
The eligibility criteria for a study eye are as follows:
Inclusion
Diabetic macular edema present on optical coherence tomography (OCT) within eight days of randomization
Media clarity, pupillary dilation, and individual cooperation sufficient for adequate fundus photographs.
Exclusions
The following exclusions apply to the study eye only (i.e., they may be present for the nonstudy eye):
Macular edema is considered to be due to a cause other than diabetic macular edema.
History of an anti-vascular endothelial growth factor (anti-VEGF) treatment for diabetic macular edema (DME) in the past 12 months or history of any other treatment for DME at any time in the past four months (such as focal/grid macular photocoagulation, intravitreous or peribulbar ).
Note, combination therapies are considered more than one medication
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2.0 mg intravitreous aflibercept
Drug: intravitreous aflibercept
1.25 mg intravitreous bevacizumab + deferred intravitreous 2.0 mg aflibercept if eye meets switch criteria
Drug: intravitreous aflibercept · Drug: Bevacizumab + Deferred Aflibercept Group
Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema. Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert. Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used. The injection will be performed using sterile technique
Also known as: Eylea
Drug page: Bevacizumab
Bevacizumab is made by Genentech, Inc. and is approved by the FDA for the treatment of metastatic colorectal cancer as well as the treatment of non-squamous non-small cell lung cancer, glioblastoma, and metastatic renal cell carcinoma. Study eyes assigned to receive bevacizumab will receive a dose of 1.25 mg provided by a single compounding pharmacy identified by the Network and distributed by the Network. The volume of the injections will be 0.05 cc. Intravitreous injection technique: The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used. The injection will be performed using a sterile technique.
Also known as: Avastin
Mean Change in Visual Acuity
Area under the curve mean change in the electronic early treatment diabetic retinopathy study visual acuity. Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision. The data presented are the best-corrected visual acuity in the study eye after protocol-defined refraction. The primary outcome was the time-averaged change in the visual-acuity letter score over a period of 104 weeks. The score was derived by calculating the area under the curve (AUC) over the 104-week period for the change in visual acuity from baseline and dividing by the length of follow-up.
Time frame: 2 years
Change in Visual Acuity From Baseline
Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision.
Time frame: 2 years
Increase in E-ETDRS Visual Acuity Letter Score
Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision.
Time frame: 2 years
Decrease in E-ETDRS Visual Acuity Letter Score
Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision.
Time frame: 2 years
Visual Acuity
Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision.
Time frame: 2 years
Optical Coherence Tomography Central Subfield Thickness Change From Baseline
Measurements made on the Cirrus device were converted to equivalent scores as would be assessed on the Spectralis device with the use of the following formula: Spectralis score = 40.78 + 0.95 × Cirrus score.
Time frame: 2 years
Optical Coherence Tomography Central Subfield Thickness Below the Sex-specific Threshold for Central-involved Diabetic Macular Edema
Optical coherence tomography (OCT) central subfield thickness equivalents for measurements obtained on Spectral domain OCT machines were 320 μm for men and 305 μm for women on the Spectralis device (Heidelberg) and were 305 μm and 290 μm, respectively on the Cirrus OCT measurement device (Zeiss).
Time frame: 2 years
Number of Visits
Time frame: 2 years
Number of Injections
All study injections were counted, including aflibercept injections received among eyes in the bevacizumab first group.
Time frame: 2 years
Number of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria
Time frame: Baseline to 12 weeks
Number of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria
Time frame: Baseline to 24 weeks
Number of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria
Time frame: Baseline to 52 weeks
Number of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria
Time frame: Baseline to 104 weeks
| Milestone | Aflibercept- Monotherapy Group | Bevacizumab-First Group |
|---|---|---|
| Started | 158 | 154 |
| Completed | 132 | 128 |
| Not completed | 26 | 26 |
| Withdrew: Death | 11 | 5 |
| Withdrew: Withdrawal by subject | 5 | 10 |
| Withdrew: Lost to follow-up | 10 | 11 |
Area under the curve mean change in the electronic early treatment diabetic retinopathy study visual acuity. Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision. The data presented are the best-corrected visual acuity in the study eye after protocol-defined refraction. The primary outcome was the time-averaged change in the visual-acuity letter score over a period of 104 weeks. The score was derived by calculating the area under the curve (AUC) over the 104-week period for the change in visual acuity from baseline and dividing by the length of follow-up.
| Letter Score | Aflibercept- Monotherapy Group | Bevacizumab-First Group |
|---|---|---|
| Overall | 15 ± 8.5 | 14 ± 8.8 |
| Female | 13.4 ± 7.9 | 13.1 ± 9.0 |
| Male | 16.7 ± 8.8 | 14.8 ± 8.6 |
| Black or African American | 14.2 ± 8.0 | 13.5 ± 10 |
| Hispanic or Latino | 12.2 ± 9.1 | 13.0 ± 9.4 |
| White | 16.8 ± 8.0 | 14.8 ± 8.3 |
Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision.
| Letter Score | Aflibercept- Monotherapy Group | Bevacizumab-First Group |
|---|---|---|
| Change in Visual Acuity From Baseline | 14.7 ± 14.5 | 15.9 ± 12.4 |
Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision.
| Eyes | Aflibercept- Monotherapy Group | Bevacizumab-First Group |
|---|---|---|
| 15 or more letters | 70 | 74 |
| 10 or more letters | 101 | 98 |
Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision.
| Eyes | Aflibercept- Monotherapy Group | Bevacizumab-First Group |
|---|---|---|
| 15 or more letters | 9 | 5 |
| 10 or more letters | 8 | 4 |
Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision.
| Eyes | Aflibercept- Monotherapy Group | Bevacizumab-First Group |
|---|---|---|
| 20/20 or better | 29 | 28 |
| 20/40 or worse | 96 | 95 |
| 20/200 or worse | 6 | 2 |
Measurements made on the Cirrus device were converted to equivalent scores as would be assessed on the Spectralis device with the use of the following formula: Spectralis score = 40.78 + 0.95 × Cirrus score.
| microns | Aflibercept- Monotherapy Group | Bevacizumab-First Group |
|---|---|---|
| Optical Coherence Tomography Central Subfield Thickness Change From Baseline | -192 ± 143 | -198 ± 160 |
Optical coherence tomography (OCT) central subfield thickness equivalents for measurements obtained on Spectral domain OCT machines were 320 μm for men and 305 μm for women on the Spectralis device (Heidelberg) and were 305 μm and 290 μm, respectively on the Cirrus OCT measurement device (Zeiss).
| Eyes | Aflibercept- Monotherapy Group | Bevacizumab-First Group |
|---|---|---|
| Optical Coherence Tomography Central Subfield Thickness Below the Sex-specific Threshold for Central-involved Diabetic Macular Edema | 76 | 70 |
| visits | Aflibercept- Monotherapy Group | Bevacizumab-First Group |
|---|---|---|
| Number of Visits | 22.0 ± 3.6 | 22.5 ± 3.4 |
All study injections were counted, including aflibercept injections received among eyes in the bevacizumab first group.
| injections | Aflibercept- Monotherapy Group | Bevacizumab-First Group |
|---|---|---|
| Number of Injections | 14.6 ± 4.1 | 16.1 ± 4.1 |
| Eyes | Bevacizumab-First Group |
|---|---|
| Number of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria | 16 |
| Eyes | Bevacizumab-First Group |
|---|---|
| Number of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria | 57 |
| Eyes | Bevacizumab-First Group |
|---|---|
| Number of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria | 88 |
| Eyes | Bevacizumab-First Group |
|---|---|
| Number of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria | 100 |
Collected over 2 Years. Non-serious events are listed at a 0.01% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Unilateral Aflibercept- Monotherapy Group | 10/116 (8.6%) | 61/116 (52.6%) | 100/116 (86.2%) |
| Unilateral Bevacizumab-First Group | 4/112 (3.6%) | 42/112 (37.5%) | 94/112 (83.9%) |
| Bilateral Participants | 3/42 (7.1%) | 18/42 (42.9%) | 40/42 (95.2%) |
| Event | Unilateral Aflibercept- Monotherapy Group | Unilateral Bevacizumab-First Group | Bilateral Participants |
|---|---|---|---|
| Congestive heart failureCardiac disorders | 9/116 | 1/112 | 4/42 |
| AnemiaBlood and lymphatic system disorders | 1/116 | 0/112 | 3/42 |
| Kidney failureRenal and urinary disorders | 1/116 | 7/112 | 2/42 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 6/116 | 2/112 | 0/42 |
| Renal failureRenal and urinary disorders | 0/116 | 0/112 | 2/42 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/116 | 0/112 | 2/42 |
| StrokeVascular disorders | 3/116 | 1/112 | 2/42 |
| Chest painGeneral disorders | 5/116 | 2/112 | 0/42 |
| Myocardial infarctionCardiac disorders | 4/116 | 3/112 | 0/42 |
| DeathGeneral disorders | 4/116 | 0/112 | 1/42 |
| Event | Unilateral Aflibercept- Monotherapy Group | Unilateral Bevacizumab-First Group | Bilateral Participants |
|---|---|---|---|
| Subconjunctival hemorrhageEye disorders | 9/116 | 10/112 | 7/42 |
| Vitreous hemorrhageEye disorders | 3/116 | 4/112 | 7/42 |
| Hypertension worsenedVascular disorders | 9/116 | 3/112 | 7/42 |
| CataractEye disorders | 19/116 | 7/112 | 6/42 |
| ColdRespiratory, thoracic and mediastinal disorders | 14/116 | 8/112 | 3/42 |
| Posterior subcapsular cataractEye disorders | 11/116 | 3/112 | 5/42 |
| HypertensionVascular disorders | 8/116 | 5/112 | 5/42 |
| FloatersEye disorders | 10/116 | 9/112 | 4/42 |
| Superficial punctate keratitisEye disorders | 1/116 | 5/112 | 4/42 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/116 | 3/112 | 4/42 |
Units in Eyes
| Age, Customized(years) | Aflibercept- Monotherapy Group | Bevacizumab-First Group | Total |
|---|---|---|---|
| age | 60 (55 to 66) | 61 (54 to 67) | 61 (54 to 66) |
| Sex/Gender, Customized(Eyes) | Aflibercept- Monotherapy Group | Bevacizumab-First Group | Total |
|---|---|---|---|
| Female | 76 | 74 | 150 |
| Male | 82 | 80 | 162 |
| Race/Ethnicity, Customized(Eyes) | Aflibercept- Monotherapy Group | Bevacizumab-First Group | Total |
|---|---|---|---|
| White | 82 | 83 | 165 |
| Black or African American | 32 | 26 | 58 |
| Hispanic or Latino | 39 | 41 | 80 |
| Asian | 2 | 2 | 4 |
| Native Hawaiian or other Pacific Islander | 1 | 1 | 2 |
| Multiple | 1 | 1 | 2 |
| Unknown or not reported | 1 | 0 | 1 |
| Type of diabetes(Eyes) | Aflibercept- Monotherapy Group | Bevacizumab-First Group | Total |
|---|---|---|---|
| Type 1 | 7 | 8 | 15 |
| Type 2 | 151 | 146 | 297 |
| Duration of diabetes(years) | Aflibercept- Monotherapy Group | Bevacizumab-First Group | Total |
|---|---|---|---|
| Median | 15 (9 to 21) | 14 (5 to 21) | 15 (7 to 21) |
| Glycated hemoglobin(Hemoglobin A1c percentage) | Aflibercept- Monotherapy Group | Bevacizumab-First Group | Total |
|---|---|---|---|
| Median | 8.0 (7.2 to 9.4) | 8.0 (6.8 to 9.4) | 8.0 (6.9 to 9.4) |
| Visual acuity letter score(units on a scale) | Aflibercept- Monotherapy Group | Bevacizumab-First Group | Total |
|---|---|---|---|
| Median | 61 (54 to 65) | 60 (51 to 65) | 60 (52 to 65) |
| Central subfield thickness(Microns) | Aflibercept- Monotherapy Group | Bevacizumab-First Group | Total |
|---|---|---|---|
| Median | 478 (401 to 579) | 496 (407 to 628) | 488 (404 to 616) |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2017 to primary completion in Dec 2021, 48 months.
Results were first posted in Apr 2024, 2 years 4 months after primary completion.
Of 65 phase 3 interventional studies under Macular Edema, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 38. This study's 48 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bevacizumab
Jaeb Center for Health Research →